Abstract: The present invention lies in the field of simulation systems for medical treatments, in particular for treatments carried out on dialysis machines. To do so, a method with which medical treatments can be performed and evaluated without the involvement of real human patients is proposed.

Abstract: A fermentation apparatus for preserving the aroma of a fermentable beverage is provided. The fermentation apparatus comprises a flow passage fluidly connectable to the headspace located above a fermentable beverage in a fermentation container. A carbon dioxide scrubber in the flow passage receives a headspace fluid mixture comprising at least carbon dioxide gas and an aromatic fluid originating from the fermenting beverage. When the headspace fluid mixture contacts the carbon dioxide scrubber, the carbon dioxide scrubber retains a modified fluid in the flow passage. The modified fluid has a lower carbon dioxide gas concentration and a higher aromatic fluid concentration than the headspace fluid mixture. The flow passage directs the modified fluid back to the headspace to at least partially retain the aromatic fluid in the fermentable beverage in the fermentation container. A method for preserving the aroma of a fermentable beverage is also provided.

Abstract: The present invention provides a powdered vinegar that comprises partly neutralized vinegar, i.e. vinegar derived acid that is partly neutralized with e.g. sodium and/or potassium hydroxide, and free vinegar derived acid. The invention also provides a process for producing such a powdered vinegar and the use of this powdered vinegar in a foodstuff or a beverage, e.g. as a preservative. The present process offers the advantage that it yields a stable, free flowing powdered vinegar that can suitably be used as a preservative in e.g. processed meat products. The powdered vinegar has a high content of free acid, is easy to dissolve and acts as an acidulant.

Abstract: A biological material manufacturing device according to an embodiment of the inventive concept includes a main body and a head unit that is rotatable on the main body. The main body includes a main groove and a first container groove connected to the main groove. The head unit includes a pillar provided in the main groove and a protruding part that protrudes from the pillar.

Abstract: The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels.

Abstract: The invention discloses a first unit (1) for treatment of a bioprocess liquid comprising a first lateral face (2), a second lateral face (3) and a front face (4) which meets the two said lateral faces. The front face comprises: a plurality of valves (7) adapted to receive and act upon one or more legs (8) of a disposable flow path (6); optionally one or more pumps (10) adapted to receive and act upon one or more legs of the disposable flow path; optionally one or more sensors (11) adapted to receive and to measure one or more parameters in one or more legs of the disposable flow path; wherein the plurality of valves and optional pumps and sensors are vertically offset from each other to give one or more legs of a disposable flow path received by said valves and optional pumps and sensors a slope of at least 3.0 degrees from the horizontal plane (h).

Abstract: Disclosed are apparatuses, systems, and methods for performing electroporation.

Abstract: The present invention provides a bioreactor controller with a simple user interface comprising a microcontroller and a linear motor. The bioreactor controller is microcontroller-based, has a greater temporal accuracy, and inexpensive. The microcontroller of the bioreactor controller selects a protocol mode and a setup mode by the user, runs the protocol mode if the setup mode is not selected by the user, stops running the protocol mode for a predetermined time if the protocol mode is selected by the user until the user is completed with calculations and record-keeping, detects movement error of the bioreactor controller, and informs the error to the user.

Abstract: A composition includes at least one carrier containing a polysaccharide, at least one antioxidant and at least one amino acid selected from cysteine, lysine, alanine and arginine. Such a composition can be used for protection of microorganisms during drying, storage and/or reconstitution. A culture powder, a process of making the culture powder, and products containing the culture powder are also disclosed.

Abstract: Methods for culturing filamentous fungi, in which the filamentous fungi are grown in a colloid of air and a fermentation medium, are provided. The methods result in more rapid and prolific growth of the filamentous fungus than has been achieved by previous methods. Biomats produced by the methods and air-medium colloids for use in the methods are also provided.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Provided are biologically pure bacterial isolates characterized by a genome structure at least 90% similar to a genome structure of a bacterial species selected from the group consisting of: Streptomyces sp. E128 having an NRRL Accession No. B-67462, Bacillus amyloliquefaciens A190 having an NRRL Accession No. B-67464, Bacillus subtilis P243 having an NRRL Accession No. B-67459, Bacillus thuringiensis M979 having an NRRL Accession No. B-67457, Massilia aurea P63 having an NRRL Accession No. B-67461, Rhodococcus sp. G706, Stenotrophomonas maltophilia E132 having an NRRL Accession No. B-67460, Streptomyces aurantiacus A918, Streptomyces badius O180, Streptomyces mirabilis B670 having an NRRL Accession No. B67463, Streptomyces scopuliridis F427 having an NRRL Accession No. B-67458, and Streptomyces sp. L219.

Abstract: The present invention provides Streptomyces coelicolor strain A3(2)_M22-2C43 obtained by inducing a point mutation in the base sequence of the DagB gene in a wild-type Streptomyces coelicolor strain A3(2) by UV radiation. Since the Streptomyces coelicolor strain A3(2)_M22-2C43 according to the present invention expresses a DagB mutant enzyme expressing little or no DagB beta-agarase or exhibiting little or no beta-agarase activity, there is no need for separate isolation and purification of DagA enzymes from culture fluid, and the culture fluid of the Streptomyces coelicolor strain A3(2)_M22-2C43 or supernatant thereof may be used to produce, from agar or agarose, neoagarose oligosaccharides with a higher content of neoagarotetraose or neoagarohexaose than that of neoagarobiose.

Abstract: Provided is a cell tissue producing method including: a cell adhesive portion forming step of forming a cell adhesive portion formed of a cell adhesive material and having a predetermined shape at a predetermined position over a substrate having a cell non-adhesive surface; and a cell locating step of discharging a cell suspension containing at least cells and a cell drying inhibitor onto the cell adhesive portion in the form of a liquid droplet to locate the cells.

Abstract: The present invention relates to apparatuses for use in electrophoretic separation of macromolecules and/or cells, and in which circulating buffer streams are not required for the electrophoretic separation of macromolecules and/or cells. In certain embodiments, the electrophoretic apparatus disclosed herein comprise a sample chamber and a harvest chamber separated by a size-exclusion membrane; non-circulating buffer chambers flanking each respective sample chamber and harvest chamber, wherein each buffer chamber is separated from each respective sample chamber and harvest chamber by an ion-permeable membrane (restriction membrane), and wherein the buffer chambers are sealed and contain a buffer solution; and an electrode positioned in each buffer chamber. Also disclosed are related methods of using the electrophoretic apparatus disclosed herein.

Abstract: Culturing of organized 3D networks of neuronal cells is provided. Individual neuronal cells are encapsulated in gel beads. The gel beads are self-assembled into ordered structures in a bioreactor. Subsequent culturing of the cells in the bioreactor leads to the formation of an organized 3D network of the neuronal cells. Such structures have many applications, especially for as says of neuronal network function and/or structure.

Abstract: This disclosure relates to methods for expanding inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) and differentiating inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells) to inner ear hair cells (e.g., atonal homolog 1 (Atoh1)+ inner ear hair cells) and the use of the inner hear supporting cells and hair cells, e.g., for identifying candidate therapeutic compounds for the treatment of hearing loss and balance loss. Additionally, the methods described herein can be used in the treatment of a subject having hearing loss and balance loss that would benefit from increased proliferation and differentiation of inner ear supporting cells (e.g., Lgr5+ inner ear supporting cells).

Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.

Abstract: Provided herein are a method of promoting osteogenic differentiation efficiency of a stem cell or of inducing chondrogenic differentiation of a stem cell, comprising treating the stem cell with a culture solution of chicken bone marrow-derived osteochondroprogenitor cells; a method of preventing or treating cartilage damage or a cartilage defect disease comprising administering to a subject in need thereof a composition comprising a differentiation-induced stem cell or differentiated chondrocyte made by said method as an active ingredient; and a method of preventing or treating a bone disease, cartilage damage, or a cartilage defect disease comprising administering to a subject in need thereof, a composition comprising a culture solution or culture concentrate of chicken bone marrow-derived osteochondroprogenitor cells as an active ingredient.

Abstract: Compositions and methods are provided for generating islet-like cell clusters. The methods include culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having Bone Morphogenetic Protein (BMP) activity (e.g., a BMP polypeptide). The effective amount of said molecule having BMP activity (e.g., BMP polypeptide) is sufficient to induce the formation of islet-like cell clusters. The methods further include treating or attenuating insulin-deficiency disorders, including type 1 diabetes. In one non-limiting embodiment, an insulin-deficiency disorder in a subject is treated or attenuated by culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having BMP activity (e.g., a BMP polypeptide) such that tho formation of islet-like cell clusters occurs.

Abstract: Provided herein are methods of producing ? cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.

Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.

Abstract: The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.

Abstract: The invention pertains to a PPA from a microorganism belonging to the family Halobacteriaceae (HPPA), for example, a PPA from Haloferax volcanii. The HPPA provided by the invention is soluble, thermostable and active at high concentrations of salt and/or organic solvent. An embodiment of the invention provides a method of increasing the rate of a reaction by adding an HPPA to the reaction mixture, wherein the reaction produces PPi, for example, an enzymatic reaction, and wherein the reaction is carried out at moderately high temperature and/or low water activity. Further embodiments of the invention provide an assay to detect the PPi released during a reaction which produces PPi by adding an HPPA to convert the PPi in to Pi and measuring the resultant Pi. The invention further pertains to an assay to monitor a reaction which produces PPi in the presence or the absence of an HPPA.

Abstract: Disclosed are mutated phosphotriesterase enzymes with improved stability and activity, as well as their use in particular for degrading organophosphorus compounds.

Abstract: Methods and systems for chromatographically purifying a botulinum neurotoxin are provided. These methods and systems allow for efficient purification of a non-complexed form of the botulinum neurotoxin in high purity and yield that can be used as an active ingredient in pharmaceutical preparations.

Abstract: A rack for holding samples and various reagents, wherein the rack may be used for loading the samples and reagents prior to using the reagents. The rack accepts complementary reagent holders, each of which contain a set of reagents for carrying out a predetermined processing operation, such as preparing biological samples for amplifying and detecting polynucleotides extracted from the samples.

Abstract: Methods, kits and compositions, in some embodiments, may include a thermostable DNA guided Argonaute protein for example TtAgo, a thermostable single-stranded DNA binding protein (SSB) for example, ET SSB, and, optionally, a strand-displacing polymerase. A SSB may allow (a) Argonaute/guide DNA complexes to substantially enhance cleavage efficiency of single- and double-stranded DNA substrates; (b) the use of longer guide DNAs (e.g., guide DNAs that are at least 24 nucleotides in length) and/or (c) increases in the sequence specificity of Argonaute-mediated binding and cleavage reactions.

Abstract: Provided herein are methods for identifying pairs of protein binding partners, mutations of which may inform the discovery of pharmaceutically useful small molecules. The methods disclosed herein may allow for the adaptation of the native protein degradation system to modulate specific disease targets at the protein level, in particular, for targets that have long been considered undruggable.

Abstract: The disclosure relates to methods for the screening, identification, and/or application of one or more microorganisms of use in imparting one or more beneficial properties to one or more plants.

Abstract: Methods for construction of DNA origami nanostructures, as well as for binding, isolation, linking, and deep sequencing information, such as both of TCR alpha and beta CDR3 mRNA, from individual cells within a mixed population of cells without the need for single cell sorting (FIG. 1).

Abstract: A structured substrate includes a substrate body having an active side. The substrate body includes reaction cavities that open along the active side and interstitial regions that separate the reaction cavities. The structured substrate includes an ensemble amplifier positioned within each of the reaction cavities. The ensemble amplifier includes a plurality of nanostructures configured to at least one of amplify electromagnetic energy that propagates into the corresponding reaction cavity or amplify electromagnetic energy that is generated within the corresponding reaction cavity.

Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR-Cas system for a Labyrinthulomycetes host cell.

Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.

Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.

Abstract: The present invention provides a double-stranded nucleic acid consisting of a sense-strand nucleic acid and an antisense-strand nucleic acid and comprising a double-strand region having at least 11 base pairs, for suppressing expression of APCS gene, in which an oligonucleotide chain having a chain length of at least 17 nucleotides and at most 30 nucleotides in the antisense-strand nucleic acid is complementary to a target APCS mRNA sequence comprising a base sequence set forth in any one of SEQ ID NOS: 1288 to 1930.

Abstract: Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).

Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.

Abstract: Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.

Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.

Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.

Abstract: The present invention relates to a recombinant E. coli cell harbouring a recombinant plasmid wherein said E. coli cell has a thermo sensitive regulation of an essential E. coli gene.

Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.

Abstract: A novel gene targeting method and a nucleotide construct for the method. The method integrates a nucleotide construct containing an interference gene in an effective gene targeting region independent of the gene by homologous recombination, thereby improving the targeting efficiency of the gene. The present invention also provides a gene targeting system for gene expression regulation and gene disruption.

Abstract: The present invention includes systems, methods and compositions for the generation of water-soluble cannabinoids in yeast, and other plant cell suspension cultures as well as novel water-soluble cannabinoid compounds. The present invention also includes compositions of matter that may contain one or more water-soluble cannabinoids.

Abstract: The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. The invention also provides transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.

Abstract: This disclosure relates to new plants and methods for increasing and decreasing synthesis of cannabinoids. The plants disclosed herein comprise unnatural ratios and concentrations of cannabinoids in plants of genus Cannabis. The methods disclosed herein comprise manipulating the biosynthetic pathway of cannabinoids to produce plants of genus Cannabis with unnatural ratios and concentrations of cannabinoids.

Abstract: The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with saline conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline conditions with respect to wild-type plants grown under similar conditions.

Abstract: The invention provides glyphosate-tolerant transgenic turfgrass plants, plant material, and propagules that have a specific transformation event. Also provided are assays for detecting the presence of the event.